Search results for "Localized disease"

showing 9 items of 9 documents

Circulating microRNA biomarkers for metastatic disease in neuroblastoma patients

2018

In this study, the circulating miRNome from diagnostic neuroblastoma serum was assessed for identification of noninvasive biomarkers with potential in monitoring metastatic disease. After determining the circulating neuroblastoma miRNome, 743 miRNAs were screened in 2 independent cohorts of 131 and 54 patients. Evaluation of serum miRNA variance in a model testing for tumor stage, MYCN status, age at diagnosis, and overall survival revealed tumor stage as the most significant factor impacting miRNA abundance in neuroblastoma serum. Differential abundance analysis between patients with metastatic and localized disease revealed 9 miRNAs strongly associated with metastatic stage 4 disease in b…

AdultMale0301 basic medicineOncologymedicine.medical_specialtyAdolescentTransplantation HeterologousMedizinDiseaseMiceNeuroblastomaYoung Adult03 medical and health sciencesInternal medicineNeuroblastomamicroRNABiomarkers TumormedicineAnimalsHumansCirculating MicroRNANeoplasm MetastasisStage (cooking)ChildAgedNeoplasm StagingNoninvasive biomarkersAged 80 and overbusiness.industryGeneral MedicineMiddle AgedSerum samplesmedicine.diseaseMicroRNAsCirculating MicroRNA030104 developmental biologyChild PreschoolLocalized diseaseFemalebusinessResearch Article
researchProduct

Circulating microRNA biomarkers for metastatic disease in neuroblastoma patients

2018

AbstractIn this study, the circulating miRNome from diagnostic neuroblastoma serum was assessed for identification of non-invasive biomarkers with potential in monitoring metastatic disease. After determining the circulating neuroblastoma miRNome, 743 miRNAs were screened in two independent cohorts of 131 and 54 patients. Evaluation of serum miRNA variance in a model testing for tumor stage, MYCN status, age at diagnosis and overall survival, revealed tumor stage as the most significant factor impacting miRNA abundance in neuroblastoma serum. Differential expression analysis between patients with metastatic and localized disease revealed 9 miRNAs strongly associated with metastatic stage 4 …

Circulating MicroRNADifferential expression analysisbusiness.industryLocalized diseaseNeuroblastomamicroRNATumor stageCancer researchMedicineDiseaseStage (cooking)businessmedicine.disease
researchProduct

Plasma hTERT mRNA discriminates between clinically localized and locally advanced disease and is a predictor of recurrence in prostate cancer patients

2012

Since the introduction of prostate-specific antigen (PSA) testing, new prostate cancer (PCa) patients are diagnosed earlier and most have localized and locally advanced disease. Current diagnosis methods lack specificity and sensitivity, leading to overdiagnosis and overtreatment of patients with low-risk organ-confined localized disease. Therefore, new non-invasive molecular tools are needed to discriminate between localized and locally advanced disease.Plasma telomerase reverse transcriptase (hTERT) mRNA levels were determined by qRT-PCR in 49 patients with localized and locally advanced PCa. Diagnostic accuracy and efficacy as a prognostic factor of biochemical recurrence of plasma hTERT…

MaleOncologyBiochemical recurrencemedicine.medical_specialtyPathologyTelomeraseClinical BiochemistryProstate cancerAntigenRecurrenceInternal medicineDrug DiscoveryBiomarkers TumormedicineHumansTelomerase reverse transcriptaseRNA MessengerOverdiagnosisTelomeraseAgedNeoplasm StagingPharmacologybusiness.industryProstatic NeoplasmsMiddle Agedmedicine.diseaseROC CurveArea Under CurveLocalized diseaseLocally advanced diseasebusinessExpert Opinion on Biological Therapy
researchProduct

Sex Differences in Colorectal Cancer Survival: Population-Based Analysis of 164,996 Colorectal Cancer Patients in Germany

2013

Risk of colorectal cancer (CRC) is considerably higher in men compared to women; however, there is inconclusive evidence of sex differences in CRC prognosis. We aimed to assess and explain sex differences in 5-year relative survival using standard and model-based period analysis among 164,996 patients diagnosed with CRC from 1997 to 2006 and reported to 11 German cancer registries covering a population of 33 million inhabitants. Age-adjusted 5-year relative survival was higher in women (64.5% vs. 61.9%, P<0.0001). A substantial survival advantage of women was confirmed in multivariate analysis after adjusting for CRC stage and subsite in subjects under 65 years of age (relative excess ri…

MaleOncologyEpidemiologyColorectal cancerlcsh:MedicineSex hormones ; Cancer detection and diagnosis ; Prognosis ; Colorectal cancer ; Rectum ; Colon ; Germany ; Age groups0302 clinical medicineGermanyRegistriesYoung adultlcsh:ScienceAged 80 and overeducation.field_of_studyMultidisciplinaryRelative survivalCancer Risk FactorsColon AdenocarcinomaAge FactorsAbsolute risk reductionMiddle Aged3. Good healthOncologyTransgender hormone therapyPopulation Surveillance030220 oncology & carcinogenesisMedicineFemale030211 gastroenterology & hepatologyColorectal NeoplasmsCancer EpidemiologyResearch ArticleAdultmedicine.medical_specialtyAdolescentClinical Research DesignPopulationRectal CancerYoung Adult03 medical and health sciencesSex FactorsInternal medicineGastrointestinal TumorsmedicineHumansMortalityeducationBiologyRetrospective StudiesAgedNeoplasm StagingPopulation Biologybusiness.industrylcsh:RCancers and NeoplasmsCancerHormonal Causes of Cancermedicine.diseaseSurgeryLocalized diseaselcsh:QbusinessPLoS ONE
researchProduct

Clinical presentation and treatment of gastrointestinal stromal tumors.

2006

Aims and background Gastrointestinal stromal tumors (GISTs), although rare, are the most common mesenchymal neoplasms affecting the gastrointestinal tract. We present our experience in the treatment of localized and metastatic disease and a review of literature. Patients and methods Nine patients were observed from April 2002 to July 2004. Eight tumors were in the gastric area and J was in the small bowel. In 5 cases, complete surgical removal was performed, and none of these patients underwent adjuvant therapy. The remaining 4 cases, with locally advanced or recurrent disease, were treated with imatinib. Results The patients with localized disease treated only by surgery did not relapse. I…

MaleReoperationCancer Researchmedicine.medical_specialtyGastrointestinal Stromal TumorsAntineoplastic AgentsDiseaseGastroenterologyPiperazines03 medical and health sciences0302 clinical medicineInternal medicinemedicineAdjuvant therapyHumansRadical surgeryProtein Kinase InhibitorsAgedGastrointestinal tractbusiness.industryStandard treatmentImatinibGeneral MedicineMiddle AgedSurvival AnalysisSurgeryPyrimidinesTreatment OutcomeImatinib mesylategastrointestinal stromal tumors treatment.OncologyChemotherapy Adjuvant030220 oncology & carcinogenesisLocalized diseaseBenzamidesImatinib MesylateFemale030211 gastroenterology & hepatologybusinessmedicine.drug
researchProduct

Surrogate endpoints for overall survival in digestive oncology trials: which candidates? A questionnaires survey among clinicians and methodologists

2010

Abstract Background Overall survival (OS) is the gold standard for the demonstration of a clinical benefit in cancer trials. Replacement of OS by a surrogate endpoint allows to reduce trial duration. To date, few surrogate endpoints have been validated in digestive oncology. The aim of this study was to draw up an ordered list of potential surrogate endpoints for OS in digestive cancer trials, by way of a survey among clinicians and methodologists. Secondary objective was to obtain their opinion on surrogacy and quality of life (QoL). Methods In 2007 and 2008, self administered sequential questionnaires were sent to a panel of French clinicians and methodologists involved in the conduct of …

OncologyCancer ResearchTime FactorsDigestive System Neoplasms[ SDV.CAN ] Life Sciences [q-bio]/Cancer0302 clinical medicineQuality of lifeSurveys and QuestionnairesMedicine030212 general & internal medicineMESH: Treatment OutcomeResponse rate (survey)MESH : Evidence-Based MedicineClinical Trials as TopicEvidence-Based MedicineMESH: Endpoint DeterminationMESH: Research DesignMESH : QuestionnairesMESH : Research Designlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens3. Good healthMESH: Reproducibility of Resultsmedicine.anatomical_structureTreatment OutcomeOncologyResearch Design030220 oncology & carcinogenesisData Interpretation StatisticalMESH: Survival AnalysisMESH : Disease-Free SurvivalMESH : Endpoint DeterminationFranceMESH : Time FactorsResearch Articlemedicine.medical_specialtyMESH: Clinical Trials as TopicEndpoint DeterminationRectum[SDV.CAN]Life Sciences [q-bio]/CancerMESH : Treatment Outcomelcsh:RC254-282Disease-Free Survival03 medical and health sciences[SDV.CAN] Life Sciences [q-bio]/CancerInternal medicineGeneticsHumansMESH : Data Interpretation StatisticalMESH : FranceSurvival analysisMESH: Humansbusiness.industrySurrogate endpointMESH: Digestive System NeoplasmsMESH : Reproducibility of ResultsMESH: QuestionnairesMESH : HumansMESH: Time FactorsCancerReproducibility of ResultsMESH: Quality of LifeMESH : Quality of Lifemedicine.diseaseSurvival AnalysisMESH : Clinical Trials as TopicMESH: FranceLocalized diseaseEndpoint DeterminationMESH: Disease-Free SurvivalQuality of LifeMESH : Digestive System NeoplasmsMESH : Survival AnalysisbusinessMESH: Data Interpretation StatisticalMESH: Evidence-Based MedicineBMC Cancer
researchProduct

SEOM clinical guideline for treatment of kidney cancer (2017)

2017

Abstract The goal of this article is to provide recommendations about the management of kidney cancer. Based on pathologic and molecular features, several kidney cancer variants were described. Nephron-sparing techniques are the gold standard of localized disease. After a randomized trial, sunitinib could be considered in adjuvant treatment in high-risk patients. Patients with advanced disease constitute a heterogeneous population. Prognostic classification should be considered. Both sunitinib and pazopanib are the standard options for first-line systemic therapy in advanced renal cell carcinoma. Based on the results of two randomized trials, both nivolumab and cabozantinib should be consid…

OncologyCancer Researchmedicine.medical_specialtyCabozantinibhumanosRonyóClinical Guides in Oncologyurologic and male genital diseasesKidneylaw.inventionPazopanib03 medical and health scienceschemistry.chemical_compound0302 clinical medicineRandomized controlled trialRenal cell carcinomalawInternal medicinemedicineHumans030212 general & internal medicineCàncerCarcinoma Renal CellCancerMolecular pathologyAdjuvant treatment of cancerneoplasias renalesSystemic therapybusiness.industrySunitinibCarcinomaCorrectionKidney cancerGeneral Medicinemedicine.diseaseKidney NeoplasmsOncologychemistry030220 oncology & carcinogenesisLocalized diseaseNivolumabbusinessKidney cancermedicine.drugTractament adjuvant del càncer
researchProduct

Metastatic Renal Cell Carcinoma to Submandibular Gland: A Rare Occurrence

2015

Approximately 20-30% of patients affected by renal cell carcinoma (RCC) present with metastatic disease, and 20% to 40% undergoing nephrectomy for clinically localized disease will develop metastases. A 53 years old female patient developed a left submandibular swelling. Four years before she experienced a left radical nephrectomy for a clear cell tumor and two years later right kidney was removed for a cancer having the same histologic subtype. In that circumstance duodenal pancreasectomy was required for infiltration of pancreatic gland. A sialoadenectomy has been performed and pathology demonstrated an intraglandular neoplasm with characteristics of a clear renal cell carcinoma. Although…

Pathologymedicine.medical_specialtymedicine.medical_treatmentSettore MED/19 - Chirurgia PlasticaMetastasiurologic and male genital diseasesSettore MED/24 - UrologiaMetastasisstomatognathic systemRenal cell carcinomamedicineClear cell renal carcinomaSalivary gland metastasisSubmandibular glandKidneySalivary glandbusiness.industryGeneral Medicinemedicine.diseaseSubmandibular glandNephrectomymedicine.anatomical_structureLocalized diseaseClear cell renal carcinoma; Metastasis; Submandibular gland; Salivary gland metastasisbusinessClear cellAnaplastology
researchProduct

Technical advances in radical retropubic prostatectomy techniques for avoiding complications. Part I: apical dissection

2003

Radical retropubic prostatectomy is currently the most widely used surgical treatment for localized prostate cancer. This once cumbersome procedure has developed technically over the last 20 years, reducing dramatically the associated complications and morbidity, e.g. blood loss, incontinence and impotence. Currently the operation is safe and is the best choice for eradicating localized disease, with little loss in quality of life. However, differences in reported outcomes indicate that there is still a need for standardization and continued efforts for surgical excellence. This review focuses on the crucial steps of the procedure, in two parts: the first covers apical dissection and the se…

medicine.medical_specialtybusiness.industryProstatectomyUrologyGeneral surgerymedicine.medical_treatmentAnastomosisSurgeryDissectionBlood lossLocalized diseaseMedicineProstate diseasebusinessSurgical treatmentRadical retropubic prostatectomyBJU International
researchProduct